Roquefort Therapeutics plc (LON:COIL – Get Free Report)’s share price fell 2.6% during mid-day trading on Thursday . The stock traded as low as GBX 9 and last traded at GBX 9.26. Approximately 180,732 shares changed hands during trading, a decline of 21% from the average daily volume of 229,381 shares. The stock had previously closed at GBX 9.50.
Roquefort Therapeutics Price Performance
The firm has a market capitalization of £39.50 million, a P/E ratio of -0.42 and a beta of 0.05. The company has a debt-to-equity ratio of 8.18, a quick ratio of 3.07 and a current ratio of 0.63. The company has a 50-day moving average price of GBX 9.95 and a 200-day moving average price of GBX 9.98.
About Roquefort Therapeutics
Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.
Featured Stories
- Five stocks we like better than Roquefort Therapeutics
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
